Evidence map›Paper›PMID 39800467›Full record

ArticleThe journal of prevention of Alzheimer's disease2025

Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study.

Théodore Decaix, François Mouton-Liger, Julien Dumurgier, Emmanuel Cognat, Agathe Vrillon, Jacques Hugon, Claire Hourregue, Elodie Bouaziz-Amar, David Wallon, Muriel Quillard Muraine and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Théodore DecaixGeriatrics Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France; Paris-Cité University, CNRS, CitCoM, F-75006, Paris, France. Electronic address: theodore.decaix@aphp.fr.
François Mouton-LigerParis-Cité University, Inserm U1144, Paris, France.
Julien DumurgierCognitive Neurology Center, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France; Paris-Cité University, Inserm U1153, Paris, France.
Emmanuel CognatParis-Cité University, Inserm U1144, Paris, France; Cognitive Neurology Center, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France.
Agathe VrillonParis-Cité University, Inserm U1144, Paris, France; Cognitive Neurology Center, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France.
Jacques HugonParis-Cité University, Inserm U1144, Paris, France; Paris-Cité University, Inserm U1153, Paris, France.
Claire HourregueCognitive Neurology Center, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France.
Elodie Bouaziz-AmarParis-Cité University, Inserm U1144, Paris, France; Biochemistry Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France.
David WallonUniv Rouen Normandie, Normandie Univ, Inserm, U1245; CHU Rouen, Department of Neurology and CNRMAJ, F-7600, Rouen, France.
Muriel Quillard MuraineDepartment of General Biochemistry, CHU Rouen, F-76000 Rouen, France.
Anne-Cécile TroussièreConsultation mémoire, centre hospitalier de Versailles, 177 rue de Versailles, 78150, Le Chesnay.
Eloi MagninUniversité de Franche-Comté, UMR INSERM 1322 LINC, CMRR, service de neurologie, CHU Besançon, F-25000 Besançon.
Emmanuelle DuronService Hospitalo-Universitaire de gériatrie. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital Paul-Brousse Villejuif FR, 12 Avenue Paul Vaillant Couturier, Villejuif, 94800, France; CESP, Team MOODS, Université Paris-Saclay, UVSQ, Le Kremlin-Bicêtre, France.
Nathalie PhilippiCMRR (Memory Resources and Research Centre), Neurology Service and Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France; ICube Laboratory UMR 7357, University of Strasbourg and CNRS, Strasbourg, France.
Frédéric BlancCMRR (Memory Resources and Research Centre), Neurology Service and Geriatrics Department, University Hospital of Strasbourg, Strasbourg, France; ICube Laboratory UMR 7357, University of Strasbourg and CNRS, Strasbourg, France.
Audrey GabelleMemory Research and Resources Center, Department of Neurology, Chu Gui de Chauliac, University of Montpellier, Institute of Neurosciences of Montpellier, France.
Bernard CroisileService de neuropsychologie, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 69677 Bron Cedex, France.
Alain JagerCabinet de neurologie SCM Jager-Gal, 6 place du Luxembourg, 57100, Thionville, France.
Florence PasquierUniv. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France.
Susanna SchraenUniv. Lille, Inserm, CHU Lille, UMR-S1172, LiCEND, Lille Neuroscience & Cognition, LabEx DISTALZ, Lille, France.
Vincent de la SayetteService de neurologie, CHU de Caen, France.
Émilie BeaufilsCentre Mémoire Ressources et Recherche (CMRR), Centre Hospitalier Universitaire de Tours, Tours, France.
Carole Miguet-AlfonsiService de biochimie, Hôpital Universitaire de Besançon, 2500, Besançon, France.
Claire PaquetParis-Cité University, Inserm U1144, Paris, France; Paris-Cité University, Inserm U1153, Paris, France.
Matthieu LilamandGeriatrics Department, Fernand Widal Lariboisière University Hospital, GHU APHP.Nord, Paris, France; Paris-Cité University, Inserm U1144, Paris, France; Paris-Cité University, Inserm U1153, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of cerebrospinal (CSF) biomarkers in the diagnosis of Alzheimer's disease (AD) has been gaining interest in clinical practice. Although their usefulness has been demonstrated, their potential value in older patients remains debated.

objectivesTo assess whether knowledge of the results of CSF AD biomarkers was associated with the same gain in diagnostic confidence in older adults > 80 than in younger patients.

designProspective multicenter study, including memory clinics physicians who completed a two-part questionnaire for all their patients addressing the requirement for assessment of Alzheimer's disease biomarkers in CSF proposed as part of routine care during the study period.

setting30 secondary or tertiary memory clinics in France. MEASUREMENTS: Clinicians indicated their diagnosis hypothesis and an estimate of their diagnostic confidence [scale 1-10]. Receiver operating characteristic (ROC) analysis, including the calculation of the area under the curve (AUC), was conducted using logistic regression to evaluate the diagnostic performance of CSF AD biomarkers.

resultsIn 813 consecutive patients, median age 70 [interquartile range (IQR) = 63 - 77] including 132 patients over 80 years, we observed a similar confidence gain in CSF biomarkers between older and younger patients, both for AD and non-AD diagnoses. In older patients, the added value of CSF biomarkers was greater when CSF biomarkers indicated AD profile whereas the initial hypothesis was "non-AD", leading to a final diagnosis of AD (2.4 ± 1.6 versus 1.1 ± 2.1, p-value, p = 0.03). ROC analyses showed similar performance of AD CSF biomarkers in older and younger patients.

conclusionCSF AD biomarkers added substantial value to clinical assessment in patients over 80. Their use seems crucial in the diagnostic process for older adults referred to memory clinics.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkerstau ProteinsAgedAged, 80 and overAge FactorsFemaleFranceHumansMaleMiddle AgedPeptide FragmentsProspective StudiesROC CurveSurveys and QuestionnairesAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAmyloid-betaClinical practiceCognitive impairmentMemory clinicsTau protein

Identifiers

PMID39800467
PMCPMC12184015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.